The good thing about POET verus Biopharm is that it is not a yes/no with the FDA. POET has been substantially derisked in the past 2 years and the main risks are being well managed based on what we have heard and seen combined with 3rd party verification and by very knowledgeable new executives.
There is still timing, execution and cost risks.